High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation

Blood

Volumn 103, Issue 4, 2004, Pages 1376-1382

  Chiocchetti, Annalisa ^b   Indelicato, Manuela ^b   Bensi, Thea ^b   Mesturini, Riccardo ^b   Giordano, Mara ^b   Sametti, Selina ^b   Castelli, Luca ^b   Bottarel, Flavia ^b   Mazzarino, Maria Clorinda ^b   Garbarini, Letizia ^b   Giacopelli, Francesca ^b   Valesini, Guido ^b   Santoro, Claudio ^b   Dianzani, Irma ^b   Ramenghi, Ugo ^b   Dianzani, Umberto ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; MESSENGER RNA; OSTEOPONTIN;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIANZANI AUTOIMMUNE LYMPHOPROLIFERATIVE DISEASE; DNA LIBRARY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HOMOZYGOTE; HUMAN; ITALY; LYMPHADENOPATHY; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; SPLENOMEGALY; T LYMPHOCYTE;

EID: 10744230010     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1748     Document Type: Article

References (42)

1. Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr. 1967;70:891-899.
2. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative sindrome. Ann Int Med. 1999;130:591-601.
3. Fisher GN, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impari apoptosis in a human lymphoproliferative syndrome. Cell. 1995;1:935-946.
4. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347-1349.
5. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
6. Dianzani U, Bragardo M, DiFranco D, et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood. 1997;89:2871-2879.
7. Ramenghi U, Bonissoni S, Migliaretti G, et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. Blood. 2000;95:3176-3182.
8. Dianzani U, Chiocchetti A, Ramenghi U. Role of inherited defects decreasing Fas function in autoimmunity. Life Sci. 2003;72:2803-2824.
9. Wang J, Zheng L, Lobito A, et al. Inherited human caspase-10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 1999;1:47-58.
10. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-1456.
11. Jackson CE, Fischer RE, Hsu AP, et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet. 1999;64:1002-1014.
12. Van Der Werff Ten Bosch J, Otten J, Thielemans K. Autoimmune lymphoproliferative syndrome type III: an indefinite disorder. Leuk Lymphoma. 2001;41:55-65.
13. O'Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol. 2000;81:373-390.
14. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055-1061.
15. Yokasaki Y, Sheppard D. Mapping of the cryptic integrin-binding site in osteopontin suggests a new mechanism by which thrombin can regulate inflammation and tissue repair. Trends Cardiovasc Med. 2000;10:155-159.
16. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin - a molecule for all seasons. QJM. 2002;95:3-13.
17. Katagiri YU, Sleeman J, Fujii H, et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 1999;59:219-226.
18. Masutani K, Akahoshi M, Tsuruya K, et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum. 2001;44:2097-2106.
19. O'Regan AW, Nau GJ, Chupp GL, Berman JS. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today. 2000;21:475-478.
20. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287:860-864.
21. Wuthrich RP, Fan X, Ritthaler T, et al. Enhanced osteopontin expression and macrophage infiltration in MRL-Fas(lpr)mice with lupus nephritis. Autoimmunity. 1998;28:139-150.
22. Weber GF, Cantor H. Differential roles of osteopontin/Eta-1 in early and late lpr disease. Clin Exp Immunol. 2001;126:578-583.
23. Katagiri Y, Mori K, Hara T, Tanaka K, Murakami M, Uede T. Functional analysis of the osteopontin molecule. Ann N Y Acad Sci. 1995;760:371-374.
24. Ohshima S, Yamaguchi N, Nishioka K, et al. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol. 2002;29:2061-2067.
25. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294:1731-1735.
26. Di Paola R, Frittitta L, Miscio G, et al. A variation in 3′ UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet. 2002;70:806-812.
27. Sytwu HK, Liblau RS, McDevitt HO. The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity. 1996;5:17-30.
28. Martinez-Lorenzo MJ, Alava MA, Gamen S, et al. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol. 1998;28:2714-2725.
29. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med. 2002;196:999-1005.
30. Tucek-Szabo CL, Andjelic S, Lacy E, Elkon KB, Nikolic-Zugic J. Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis: activation-induced death can occur without Fas receptor. J Immunol. 1996;156:192-200.
31. O'Regan AW, Hayden JM, Berman JS. Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol. 2000;68:495-502.
32. Iizuka J, Katagiri Y, Tada N, et al. Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies. Lab Invest. 1998;78:1523-1533.
33. Prud'homme GJ, Kono DH, Theofilopoulos AN. Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1 beta, interleukin-1 and interferon-gamma mRNA in the lymph nodes of lupus-prone mice. Mol Immunol. 1995;32:495-503.
34. Yanagi K, Haneji N, Hamano H, Takahashi M, Higashiyama H, Hayashi Y. In vivo role of IL-10 and IL-12 during development of Sjogren's syndrome in MRL/ lpr mice. Cell Immunol. 1996;168:243-250.
35. Takahashi S, Fossati L, Iwamoto M, et al. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J Clin Invest. 1996;97:1597-1604.
36. Yin Z, Bahtiyar G, Zhang N, et al. IL-10 regulates murine lupus. J Immunol. 2002;169:2148-2155.
37. Watanabe N, Ikuta K, Nisitani S, Chiba T, Honjo T. Activation and differentiation of autoreactive B-1 cells by interleukin 10, induce autoimmune hemolytic anemia in Fas-deficient antierythrocyte immunoglobulin transgenic mice. J Exp Med. 2002;196:141-146.
38. Mori K, Kobayashi S, Inobe M, et al. In vivo cytokine gene expression in various T cell subsets of the autoimmune MRL/Mp-lpr/lpr mouse. Autoimmunity. 1994;17:49-57.
39. Patarca R, Wei FY, Singh P, Morasso MI, Cantor H. Dysregulated expression of the T cell cytokine Eta-1 in CD4-8-lymphocytes during the development of murine autoimmune disease. J Exp Med. 1990;172:1177-1183.
40. Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol. 2002;168:2096-2099.
41. Forton AC, Petri MA, Goldman D, Sullivan KE. An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus. Hum Mutat. 2002;19:459-462.
42. Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K. Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J Neuroimmunol. 2003;136:125-129.